Market Cap 14.60B
Revenue (ttm) 14.74B
Net Income (ttm) -634.20M
EPS (ttm) N/A
PE Ratio 5.48
Forward PE 5.15
Profit Margin -4.30%
Debt to Equity Ratio 1.07
Volume 10,317,079
Avg Vol 9,124,516
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 98%
Beta 0.80
Analysts Sell
Price Target $12.69

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
CoulterB
CoulterB Jan. 14 at 8:16 PM
$VTRS cup and handle.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 3:30 PM
$LXRX + $VTRS = UAE , Canada, Australia.... it's coming... you are not wrong my friend https://investor.viatris.com/static-files/1212d130-d97f-4b22-aeca-bb3657dfc802 also $LXRX + $NVO by the way. ; ) https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/
0 · Reply
SniperPro
SniperPro Jan. 14 at 3:02 PM
$NVO $PFE $LXRX $VTRS I TOLD YOU… VIATRIS DOESN’T WASTE TIME! THEIR CEO'S GOT MARBLES! HE WANTS THINGS DONE YESTERDAY... THE MAN IS A CONQUEROR, AND THEIR SALES TEAM AND LAWYERS DON’T MESS AROUND! Anticipated Regulatory Decisions and Launches H1 2026 Thanks Iman, awesome find!!! YES... YES... YES.... LFG
0 · Reply
Tangerine_Trades
Tangerine_Trades Jan. 14 at 1:27 PM
$VTRS Revenue growth moving to mid-single digits while the stock is still priced as a failing company. 14% FCF yield and likely to rise as both top line growth and cost savings effort make their way to the bottom line. There’s a large margin of safety on this stock and big upside.
0 · Reply
SniperPro
SniperPro Jan. 14 at 12:45 AM
$PFE $LXRX $NVO $VTRS YES... YES... YES.... SOTA UAE APPROVED! Dubai: The Emirates Drug Establishment (EDE) on Monday announced that it has authorised Inpefa® (sotagliflozin), a new drug for heart failure, making the UAE the second country worldwide to approve the therapy, in yet another step reflecting the UAE’s leadership in adopting pharmaceutical innovations and strengthening its healthcare system. Inpefa® (sotagliflozin) is the first dual SGLT1 and SGLT2 inhibitor approved for the treatment of heart failure. It is an oral medication that helps regulate blood glucose levels while supporting heart and kidney health. The treatment has been approved to reduce the risk of death from cardiovascular diseases, lower hospital admissions due to heart failure, and decrease urgent medical visits associated with the condition among adults with heart failure, type 2 diabetes, chronic kidney disease, or other cardiovascular risk factors, EDE stated.
0 · Reply
FHMaitland
FHMaitland Jan. 13 at 10:44 PM
$VTRS Absurdly underpriced. $20 by end of year conservatively. $30 is certainly possible.
0 · Reply
bklynlou
bklynlou Jan. 13 at 9:13 PM
$VTRS Happy to see the 5%, but what did they announce at the analyst meeting that got everyone all excited?
1 · Reply
mamba_9
mamba_9 Jan. 13 at 7:32 PM
$VTRS LFG
0 · Reply
CoulterB
CoulterB Jan. 13 at 5:48 PM
$VTRS exciting products in the pipeline.
0 · Reply
OMM22
OMM22 Jan. 13 at 5:24 PM
$VTRS how high can we go
0 · Reply
Latest News on VTRS
Viatris Provides Pipeline Update on Four Regulatory Milestones

Dec 18, 2025, 6:59 AM EST - 27 days ago

Viatris Provides Pipeline Update on Four Regulatory Milestones


Viatris to Participate in Upcoming Investor Conferences

Nov 24, 2025, 8:00 AM EST - 7 weeks ago

Viatris to Participate in Upcoming Investor Conferences


Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:46 PM EST - 2 months ago

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript


Viatris Announces Quarterly Dividend

Nov 4, 2025, 6:59 AM EST - 2 months ago

Viatris Announces Quarterly Dividend


Viatris: Indore Plant Could Boost 2026 Numbers

Sep 25, 2025, 1:16 PM EDT - 3 months ago

Viatris: Indore Plant Could Boost 2026 Numbers


Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:02 AM EDT - 5 months ago

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript


Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 2:17 PM EDT - 6 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review


Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 6 months ago

Viatris eye therapy fails to meet late-stage trial goal


Viatris: A Contrarian Bet With Virtually No Downside

Jul 16, 2025, 3:19 AM EDT - 6 months ago

Viatris: A Contrarian Bet With Virtually No Downside


CoulterB
CoulterB Jan. 14 at 8:16 PM
$VTRS cup and handle.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 3:30 PM
$LXRX + $VTRS = UAE , Canada, Australia.... it's coming... you are not wrong my friend https://investor.viatris.com/static-files/1212d130-d97f-4b22-aeca-bb3657dfc802 also $LXRX + $NVO by the way. ; ) https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/
0 · Reply
SniperPro
SniperPro Jan. 14 at 3:02 PM
$NVO $PFE $LXRX $VTRS I TOLD YOU… VIATRIS DOESN’T WASTE TIME! THEIR CEO'S GOT MARBLES! HE WANTS THINGS DONE YESTERDAY... THE MAN IS A CONQUEROR, AND THEIR SALES TEAM AND LAWYERS DON’T MESS AROUND! Anticipated Regulatory Decisions and Launches H1 2026 Thanks Iman, awesome find!!! YES... YES... YES.... LFG
0 · Reply
Tangerine_Trades
Tangerine_Trades Jan. 14 at 1:27 PM
$VTRS Revenue growth moving to mid-single digits while the stock is still priced as a failing company. 14% FCF yield and likely to rise as both top line growth and cost savings effort make their way to the bottom line. There’s a large margin of safety on this stock and big upside.
0 · Reply
SniperPro
SniperPro Jan. 14 at 12:45 AM
$PFE $LXRX $NVO $VTRS YES... YES... YES.... SOTA UAE APPROVED! Dubai: The Emirates Drug Establishment (EDE) on Monday announced that it has authorised Inpefa® (sotagliflozin), a new drug for heart failure, making the UAE the second country worldwide to approve the therapy, in yet another step reflecting the UAE’s leadership in adopting pharmaceutical innovations and strengthening its healthcare system. Inpefa® (sotagliflozin) is the first dual SGLT1 and SGLT2 inhibitor approved for the treatment of heart failure. It is an oral medication that helps regulate blood glucose levels while supporting heart and kidney health. The treatment has been approved to reduce the risk of death from cardiovascular diseases, lower hospital admissions due to heart failure, and decrease urgent medical visits associated with the condition among adults with heart failure, type 2 diabetes, chronic kidney disease, or other cardiovascular risk factors, EDE stated.
0 · Reply
FHMaitland
FHMaitland Jan. 13 at 10:44 PM
$VTRS Absurdly underpriced. $20 by end of year conservatively. $30 is certainly possible.
0 · Reply
bklynlou
bklynlou Jan. 13 at 9:13 PM
$VTRS Happy to see the 5%, but what did they announce at the analyst meeting that got everyone all excited?
1 · Reply
mamba_9
mamba_9 Jan. 13 at 7:32 PM
$VTRS LFG
0 · Reply
CoulterB
CoulterB Jan. 13 at 5:48 PM
$VTRS exciting products in the pipeline.
0 · Reply
OMM22
OMM22 Jan. 13 at 5:24 PM
$VTRS how high can we go
0 · Reply
tanner12oz
tanner12oz Jan. 13 at 5:18 PM
$VTRS some buying here
0 · Reply
mamba_9
mamba_9 Jan. 9 at 8:27 PM
0 · Reply
ShirleyG
ShirleyG Jan. 7 at 3:32 PM
$VTRS $13-$15 let's goooo⏳️🔥🚀
0 · Reply
SniperPro
SniperPro Jan. 7 at 2:50 PM
$LXRX WE NEED BIG PHARMA TO PUSH SALES… AND IT’S COMING — FAST, FURIOUS, AND WHEN YOU LEAST EXPECT IT. NO WARNING. NO MERCY. BOOM. $NVO IS SALIVATING FOR SOTA SALES US/EU — PRESSURE BUILDING, CLOCK TICKING, EXIT DOORS SLAMMING SHUT. WATCH. WAIT. THEN SEE RESULTS EXTRAPOLATE LIKE NEVER BEFORE. $VTRS NEXT QR REPORTING SOTA OVERSEAS RESULTS — THE PLOT THICKENS. GLOBAL NUMBERS START HITTING THE TAPE. INTERNATIONAL MOMENTUM. UNIGNORABLE DATA. EXPECT SURPRISES — THE KIND THAT FORCE REPRICING FAST. PRESSURE BUILDS. NARRATIVES BREAK. WATCH WHAT HAPPENS WHEN OVERSEAS RESULTS HIT — THIS IS WHERE IT TURNS LOUD.
0 · Reply
mamba_9
mamba_9 Jan. 6 at 1:33 PM
$VTRS great valuation
0 · Reply
ShirleyG
ShirleyG Jan. 5 at 8:02 PM
$VTRS $15 why not🤑⚡️🏆🎉🚀
0 · Reply
ShirleyG
ShirleyG Jan. 2 at 6:54 AM
$VTRS 📈$12$15📈🚀 🚀🚀🚀🚀🚀🚀🚀
0 · Reply
LamboMax
LamboMax Dec. 30 at 9:42 PM
0 · Reply
FHMaitland
FHMaitland Dec. 30 at 2:49 PM
$VTRS Weird, weird stock. I've owned it for years and while I'm not down, it's been frustrating watching so many other equities skyrocket while Viatris does basically nothing. Super low PE, big buyback, decent div...I don't get why this isn't at least $20 a share. Anyway, I'm long a little over 1,100 shares and cautiously optimistic.
3 · Reply
ALRAE
ALRAE Dec. 29 at 7:10 PM
0 · Reply
Broview
Broview Dec. 28 at 2:32 PM
$VTRS growth and dividend both attractive?
0 · Reply
MarketPilotElite
MarketPilotElite Dec. 27 at 6:21 AM
$VTRS Risk tolerance remains selective and tied closely to execution credibility. Competitive advantages must begin to appear in core metrics. Credible progress tends to compress risk premiums. Without validation, volatility may persist longer than expected.
1 · Reply